Pharmascience Inc. v. Meda AB et al - Nov 16, 2021 - Part 3

Sean Prouse1h 51min

Speaker 1

00:00

Sorry, you may have to zoom out a little or if you can scroll down on on page eight. And then if you see there's the section forecast reports. And there's two scenarios. And there is reference to launch first to market reg approval being a 50% chance and launch second to market being a 50% chance. So again, anticipation of potential generic competition as of this time in 2013. It's a

Unknown Speaker

00:33

possibility, yes.

Speaker 1

00:35

When in fact, it's, uh, you've pegged it at a 5050 chance that someone may beat you to market.

Speaker 2

00:42

The reason we put 5050 is because we don't know. So that was the reason for that.

Speaker 1

00:57

And if we could turn up PMS production 143, which is which was marked as exhibit 11, I believe. And I believe as of this timeframe, if we scroll down, we'll see the same reference to a 50% chance of being first to market 50% chance of being second. Yes.

Speaker 1

01:32

If you could actually scroll back up, please Miss torrent? Okay. And we see there's a reference in the projected launch date. And I believe you discussed this briefly this morning to NOC plus five days for narcotic lock license. And I just want to clarify, confirm that's five business days, right. That was the assumption Yes. The quickest possible would be five business days.

Processing audio...